About Alder Biopharmaceuticals
Alder Biopharmaceuticals is a company based in Bothell (United States) founded in 2004 was acquired by Lundbeck in September 2019.. Alder Biopharmaceuticals has raised $105.1 million across 5 funding rounds from investors including TPG, Lundbeck and Ventures West. Alder Biopharmaceuticals operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter Bothell, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
121 people
Software Development Team
85 people
Sales and Marketing
47 people
Finance and Accounting
39 people
Human Resources and Administration
38 people
Product Management Team
35 people
Senior Team
34 people
Legal and Compliance
24 people
Unlock access to complete
Funding Insights of Alder Biopharmaceuticals
Alder Biopharmaceuticals has successfully raised a total of $105.1M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $250.0M
-
First Round
First Round
(09 Aug 2005)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2018 | Amount | Post-IPO - Alder Biopharmaceuticals | Valuation |
investors |
|
| Apr, 2012 | Amount | Series D - Alder Biopharmaceuticals | Valuation | Novo Holdings | |
| Jan, 2008 | Amount | Series C - Alder Biopharmaceuticals | Valuation | Delphi Ventures , TPG |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alder Biopharmaceuticals
Alder Biopharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Lundbeck and Ventures West. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in Canadian companies are made by Ventures West.
|
Founded Year | Domain | Location | |
|
Investments are made in life sciences firms across all stages.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alder Biopharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alder Biopharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alder Biopharmaceuticals Comparisons
Competitors of Alder Biopharmaceuticals
Alder Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alder Biopharmaceuticals
Frequently Asked Questions about Alder Biopharmaceuticals
When was Alder Biopharmaceuticals founded?
Alder Biopharmaceuticals was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Alder Biopharmaceuticals located?
Alder Biopharmaceuticals is headquartered in Bothell, United States. It is registered at Bothell, Washington, United States.
Is Alder Biopharmaceuticals a funded company?
Alder Biopharmaceuticals is a funded company, having raised a total of $105.1M across 5 funding rounds to date. The company's 1st funding round was a Series C of $40M, raised on Aug 09, 2005.
What does Alder Biopharmaceuticals do?
Alder Biopharmaceuticals was founded in 2004 and is headquartered in Bothell, United States. Operations are centered in the biopharmaceutical sector, where humanized monoclonal antibody therapeutics are developed to address migraine and inflammatory diseases. Research and development activities are focused on innovative treatments within this domain, with clinical advancements pursued through targeted antibody technologies. The companys efforts are directed toward unmet medical needs in neurology and immunology.
Who are the top competitors of Alder Biopharmaceuticals?
Alder Biopharmaceuticals's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Who are Alder Biopharmaceuticals's investors?
Alder Biopharmaceuticals has 8 investors. Key investors include TPG, Lundbeck, Ventures West, Delphi Ventures, and H.I.G. Capital.